AsianScientist (Mar. 1, 2018) – STA Pharmaceutical Co., Ltd. (Wuxi STA) and Regulus Therapeutics Inc. (Regulus) have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.
Wuxi STA is a leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing. It recently established oligonucleotide R&D labs at both its facilities in San Diego, California, and Changzhou, China.
The state-of-the-art oligonucleotide GMP manufacturing facility at Changzhou will become operational later this year. Regulus is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.
Under the agreement, Wuxi STA will become a new strategic development and manufacturing partner for Regulus’ preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how and training in the field of oligonucleotide scale-up.
“We are excited to establish a high quality oligonucleotide research, development and manufacturing technology platform, and it’s a great honor to work with an innovative, pioneering company such as Regulus,” said Dr. Chen Minzhang, CEO of Wuxi STA.
“This partnership will allow Wuxi STA to expedite Regulus’ oligonucleotide therapeutics programs into the clinic, and eventually, to patients. Through our newly established global quality oligonucleotide platform, we strive to make life-saving oligonucleotide therapeutics more affordable and available to patients worldwide,” he added.
“By partnering with a well-respected, world-class organization like Wuxi STA, we gain their commitment to support our long-term development and commercialization goals,” said Mr. Jay Hagan, president and CEO of Regulus.
———
Source: WuXi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
